AI in Pharma: CEO Calls for Custom Solutions to Navigate Complex Landscape
Artificial Intelligence (AI) is rapidly evolving, promising transformative potential in the pharmaceutical industry. However, the sector's emphasis on precision, regulation, and patient safety demands tailored AI solutions. Sam Sammane, CEO of TheoSym, underscores the need for custom-built AI to navigate the complex landscape of pharmaceutical data and Good Manufacturing Practice (GMP) requirements.
AI's role in pharma spans pre-approval stages like drug discovery and clinical trials, and post-approval aspects such as quality control, manufacturing, and patient outcomes. Generic AI systems, while impressive in language tasks, fall short in critical applications where human lives are at stake. Sammane, previously at GeoSpock, advocates for AI designed specifically for pharmaceutical tasks.
Pharmaceutical data is vast, interconnected, and complex, necessitating hybrid solutions that blend structured systems with innovative models. Customization of AI systems is vital to avoid pitfalls like hallucinations, incomplete context, or misleading output. GMP, though burdensome, is indispensable for ensuring drug safety, effectiveness, and traceability.
AI's potential in pharma is undeniable, but it must be harnessed responsibly. Custom-built AI tailored to pharmaceutical tasks, data complexity, and GMP requirements is essential. By investing in domain-specific AI, the industry can enhance quality assurance workflows, improve patient outcomes, and ensure the safety and efficacy of pharmaceutical products.
